Skip to content

    Cervical Cancer Health Center

    Medical Reference Related to Cervical Cancer

    1. Endometrial Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Changes to This Summary (10 / 22 / 2014)

      About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current

    2. Cervical Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Questions or Comments About This Summary

      If you have questions or comments about this summary, please send them to Cancer.gov through the Web site's Contact Form. We can respond only to email messages written in English.

    3. Gestational Trophoblastic Disease Treatment (PDQ®): Treatment - Patient Information [NCI] - General Information About Gestational Trophoblastic Disease

      Gestational trophoblastic disease (GTD) is a group of rare diseases in which abnormal trophoblast cells grow inside the uterus after conception.Gestational trophoblastic disease (GTD) develops inside the uterus from tissue that forms after conception (the joining of sperm and egg). This tissue is made of trophoblast cells and normally surrounds the fertilized egg in the uterus. Trophoblast cells help connect the fertilized egg to the wall of the uterus and form part of the placenta (the organ that passes nutrients from the mother to the fetus).Sometimes there is a problem with the fertilized egg and trophoblast cells. Instead of a healthy fetus developing, a tumor forms. Until there are signs or symptoms of the tumor, the pregnancy will seem like a normal pregnancy.Most GTD is benign (not cancer) and does not spread, but some types become malignant (cancer) and spread to nearby tissues or distant parts of the body.Gestational trophoblastic disease (GTD) is a general term that

    4. Endometrial Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - In Situ Cervical Cancer Treatment

      Consensus guidelines have been issued for managing women with cervical intraepithelial neoplasia or adenocarcinoma in situ.[1] Properly treated, tumor control of in situ cervical carcinoma should be nearly 100%. Either expert colposcopic-directed biopsy or cone biopsy is required to exclude invasive disease before therapy is undertaken. A correlation between cytology and colposcopic-directed biopsy is also necessary before local ablative therapy is done. Even so, unrecognized invasive disease treated with inadequate ablative therapy may be the most common cause of failure.[2] Failure to identify the disease, lack of correlation between the Pap smear and colposcopic findings, adenocarcinoma in situ, or extension of disease into the endocervical canal makes a laser, loop, or cold-knife conization mandatory. The choice of treatment will also depend on several patient factors including age, desire to preserve fertility, and medical condition. Most importantly, the extent of disease must

    5. Endometrial Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Overview

      Note: Separate PDQ summaries on Cervical Cancer Prevention,Cervical Cancer Treatment,and Levels of Evidence for Cancer Screening and Prevention Studies are also available. Screening With the Papanicolaou (Pap) Test: Benefits Based on solid evidence,regular screening of appropriate women for cervical cancer with the Pap test reduces mortality from cervical cancer. The benefits of screening ...

    6. Endometrial Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - General Information About Cervical Cancer

      WebMD explains the types of cervical cancer and the prognosis when you're diagnosed in different stages.

    7. Endometrial Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Recurrent and Resistant Gestational Trophoblastic Neoplasia

      Recurrent gestational trophoblastic neoplasia (GTN) is cancer that has recurred (come back) after it has been treated. The cancer may come back in the uterus or in other parts of the body.Gestational trophoblastic neoplasia that does not respond to treatment is called resistant GTN.

    8. Endometrial Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - nci_ncicdr0000062817-nci-header

      This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Cervical Cancer Prevention

    9. Endometrial Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Recurrent Uterine Sarcoma

      There is currently no standard therapy for patients with recurrent disease. These patients should be entered into an ongoing clinical trial. Patients who present with uterine sarcoma have been treated on a series of phase II studies by the Gynecologic Oncology Group, including the GOG-87B trial, for example. These chemotherapy studies have documented some antitumor activity for cisplatin, doxorubicin, and ifosfamide. These studies have also documented differences in response leading to separate trials for patients with carcinosarcomas and leiomyosarcomas. As an example, in patients previously untreated with chemotherapy, ifosfamide had a 32.2% response rate in patients with carcinosarcomas,[1] a 33% response rate in patients with endometrial stromal cell sarcomas,[2] and a 17.2% partial response rate in patients with leiomyosarcomas.[3] Doxorubicin in combination with dacarbazine or cyclophosphamide is no more active than doxorubicin alone for recurrent disease.[4,5] Cisplatin has

    10. Endometrial Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - nci_ncicdr0000062938-nci-header

      This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Uterine Sarcoma Treatment

    Displaying 21 - 30 of 159 Articles << Prev Page 1 2 3 4 5 6 7 8 9 10 Next >>

    Today on WebMD

    cancer cell
    HPV is the top cause. Find out more.
    doctor and patient
    Get to know the symptoms.
     
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Lung cancer xray
    See it in pictures, plus read the facts.
     
    Integrative Medicine Cancer Quiz
    QUIZ
    Lifestyle Tips for Depression Slideshow
    SLIDESHOW
     
    Screening Tests for Women
    Slideshow
    what is your cancer risk
    HEALTH CHECK